Rocket Pharmaceuticals’ pediatric priority review voucher sale ties regulatory acceleration to cash runway for later-stage gene therapy development. The report links the $180 million non-dilutive proceeds to the company’s Danon disease program in pivotal testing. The setup is notable for how it supports a rare disease timeline where manufacturing scale and clinical execution can become the rate-limiting steps. In this case, the voucher effectively converts approval momentum into funding for a downstream program rather than expanding only the commercial footprint. The move also illustrates how companies with eligible vouchers can bridge gaps between milestone-driven capital needs and keep gene therapy assets on schedule.